- Industry Leader Brings 20+ Years of Cosmetic
Expertise to the Performance Beauty Category
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a
focus on building an aesthetic portfolio of consumer brands, has
named Ms. Tomoko Yamagishi-Dressler as Chief Marketing Officer
(CMO), effective today. Yamagishi-Dressler is an accomplished
executive with more than two decades of established excellence
leading omnichannel marketing for global beauty companies. A true
strategist, Yamagishi-Dressler has successfully driven profitable
business growth and increased equity for an iconic portfolio of
industry brands.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230818688654/en/
Tomoko Yamagishi-Dressler, Chief
Marketing Officer, Evolus, Inc. (Photo: Evolus)
“Tomoko brings incredible expertise in the beauty business, as
well as deep global and omnichannel marketing experience for
prominent cosmetic brands that will help power Evolus in our
journey to becoming a leading performance beauty company,” said
David Moatazedi, President and CEO at Evolus. “This is the right
time to focus our efforts on building Jeuveau® into a household
name. As our new CMO, Tomoko will play a crucial role in leveraging
the recent successful rebranding of our flagship product Jeuveau®
and further expanding our loyal consumer base. In addition, she
will lead commercial efforts to prepare for the launch of Evolysse™
– our line of five late-stage dermal fillers – in the U.S.
beginning in 2025.”
Most recently, Yamagishi-Dressler was Global Chief Marketing
Officer at Beautyblender where she elevated Beautyblender’s global
market position and drove category leadership for the brand’s
namesake makeup tool in Sephora and ULTA stores across the United
States.
From 2000 to 2020, Yamagishi-Dressler held roles of increasing
responsibility at Shiseido, one of the world’s top 5 beauty
companies. During her tenure, Yamagishi-Dressler relocated to
Shiseido’s headquarters in Japan in the appointed role of Group
Leader for Global Skincare Marketing. While overseas, she
introduced a new portfolio of products to strengthen the company’s
competitive industry position.
Following, Yamagishi-Dressler returned to the United States as
Senior Vice President of Marketing & Sales, overseeing the
digital transformation of the company and responsible for sales,
e-commerce, marketing and media for Shiseido’s ultra-prestige
division. Earlier in her career, Yamagishi-Dressler worked at
Chanel Inc. and Victoria’s Secret Beauty Company.
Yamagishi-Dressler is a graduate of the prestigious MBA program at
Harvard Business School.
“I am inspired by Evolus’ commitment to innovation. Aesthetics
is a fast-growing segment in our industry and one that is currently
experiencing greater consumer acceptance and awareness,” said Ms.
Yamagishi-Dressler. “By leveraging my extensive background in
luxury skincare marketing, I plan to build on this positive
momentum to instill more customer confidence in the performance
beauty category. I am fortunate to be joining Evolus at such a
pivotal time of growth and look forward to being an instrumental
part of the company’s future.”
About Evolus, Inc.
Evolus (Nasdaq: EOLS) is a performance beauty company evolving
the aesthetic neurotoxin market for the next generation of beauty
consumers through its unique, customer-centric business model and
innovative digital platform. Our mission is to become a global,
multi-product aesthetics company based on our flagship product,
Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin
dedicated exclusively to aesthetics and manufactured in a
state-of-the-art facility using Hi-Pure™ technology. Evolus is
expanding its product portfolio having entered into a definitive
agreement to be the exclusive U.S. distributor of Evolysse™, a line
of five unique dermal fillers currently in late-stage development.
Visit us at www.evolus.com, and follow us on LinkedIn, Twitter,
Instagram or Facebook.
Forward-Looking Statements
This press release contains forward-looking statements as
defined under the Private Securities Litigation Reform Act of 1995
that involve risks and uncertainties, including statements about
future events, our business, financial condition, results of
operations and prospects, our industry and the regulatory
environment in which we operate. Any statements contained herein
that are not statements of historical or current facts are
forward-looking statements. In some cases, you can identify
forward-looking statements by terms such as “anticipate,”
“believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,”
“potential,” “predict,” “project,” “should,” “will,” “would” or the
negative of those terms, or other comparable terms intended to
identify statements about the future. The company’s forward-looking
statements include, but are not limited to, statements related to
market conditions and consumer demand or the company’s
products.
The forward-looking statements included herein are based on our
current expectations, assumptions, estimates and projections, which
we believe to be reasonable, and are subject to risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by the forward-looking statements.
These risks and uncertainties, all of which are difficult or
impossible to predict accurately and many of which are beyond our
control, include, but are not limited to uncertainties associated
with our ability to comply with the terms and conditions in the
Medytox Settlement Agreements, our ability to fund our future
operations or obtain financing to fund our operations, unfavorable
global economic conditions and the impact on consumer discretionary
spending, uncertainties related to customer and consumer adoption
of Jeuveau® and EvolysseTM, the efficiency and operability of our
digital platform, competition and market dynamics, our ability to
successfully launch and commercialize our products in new markets,
including the EvolysseTM dermal filler product line in the U.S.,
our ability to maintain regulatory approvals of Jeuveau® or obtain
regulatory approvals for new product candidates or indications, our
reliance on Symatese to achieve regulatory approval for the
EvolysseTM dermal filler product line in the U.S., and other risks
described in our filings with the Securities and Exchange
Commission, including in the section entitled “Risk Factors” in our
Annual Report on Form 10-K and our Quarterly Report on Form 10-Q
for the quarter ended June 30, 2023 expected to be filed with the
Securities and Exchange Commission on or about August 8, 2023.
These filings can be accessed online at www.sec.gov. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. Except as
required by law, we undertake no obligation to update or revise any
forward-looking statements to reflect new information, changed
circumstances or unanticipated events. If we do update or revise
one or more of these statements, investors and others should not
conclude that we will make additional updates or corrections.
Jeuveau® and Evolysse™ are trademarks of Evolus, Inc. Hi-Pure™
is a trademark of Daewoong Pharmaceutical Co, Ltd.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230818688654/en/
Investor Contact: David K. Erickson
Vice President, Investor Relations Tel: 949-966-1798 Email:
david.erickson@evolus.com
Media Contact: Email: media@evolus.com
Evolus (NASDAQ:EOLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Evolus (NASDAQ:EOLS)
Historical Stock Chart
From Apr 2023 to Apr 2024